Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Depomed
ClinicalTrials.gov Identifier:
NCT00777023
First received: October 21, 2008
Last updated: February 21, 2012
Last verified: February 2012
  Purpose

Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women


Condition Intervention Phase
Hot Flashes
Drug: Gabapentin Extended-Release (G-ER) 1200 mg
Drug: Gabapentin Extended-Release (G-ER) 1800 mg
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women

Resource links provided by NLM:


Further study details as provided by Depomed:

Primary Outcome Measures:
  • Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment [ Time Frame: At baseline and 4 weeks of treatment ] [ Designated as safety issue: No ]
    Mean change from baseline in average daily number of moderate or severe hot flashes at stable dose week (SDW) 4 of treatment relative to placebo; last observation carried forward (LOCF) analysis

  • Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 12 Weeks of Treatment [ Time Frame: At baseline and 12 weeks of treatment ] [ Designated as safety issue: No ]
    Mean change from baseline in average daily number of moderate or severe hot flashes at stable dose week (SDW) 12 of treatment relative to placebo; last observation carried forward (LOCF) analysis

  • Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 4 Weeks of Treatment [ Time Frame: At baseline and 4 weeks of treatment ] [ Designated as safety issue: No ]

    Mean change from baseline in average daily severity score of moderate or severe hot flashes at stable dose week (SDW) 4 of treatment relative to placebo; last observation carried forward (LOCF) analysis.

    Severity of hot flashes is scored on a scale of 1 to 3 where 1=mild, 2=moderate, 3=severe.


  • Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 12 Weeks of Treatment [ Time Frame: At baseline and 12 weeks of treatment ] [ Designated as safety issue: No ]

    Mean change from baseline in average daily severity score of moderate or severe hot flashes at stable dose week (SDW) 12 of treatment relative to placebo; last observation carried forward (LOCF) analysis.

    Severity of hot flashes is scored on a scale of 1 to 3 where 1=mild, 2=moderate, 3=severe.



Enrollment: 565
Study Start Date: October 2008
Study Completion Date: October 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: G-ER 1200 mg
Gabapentin extended-release (G-ER) 1200 mg
Drug: Gabapentin Extended-Release (G-ER) 1200 mg
G-ER 1200 mg daily dosage given as two 600-mg tablets.
Other Name: Gabapentin
Experimental: G-ER 1800 mg
Gabapentin extended-release (G-ER) 1800 mg
Drug: Gabapentin Extended-Release (G-ER) 1800 mg
G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
Other Name: Gabapentin
Placebo Comparator: Sugar Pill
Placebo 1200 mg or 1800 mg
Drug: Placebo
Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Other Name: Placebo; sugar pill

Detailed Description:

The primary study objective is to assess the efficacy of G-ER dosed in either of the following regimens:

G-ER 1200mg daily (single evening dose)

G-ER 1800mg daily (dosed asymmetrically; 600mg AM/1200mg PM)

compared to placebo in reducing the average daily frequency and severity score of moderate to severe hot flashes in postmenopausal women after 4 weeks and 12 weeks of treatment with a stable dose, compared with the baseline week.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Postmenopausal women aged 18 to 70 years experiencing ≥7 moderate to severe hot flashes per day (or ≥50 per week) accompanied by sweating during previous 30 days or longer.
  2. Had amenorrhea for ≥12 months, amenorrhea for 6 to 12 months with serum follicle-stimulating hormone (FSH) levels >40 mIU/mL, or was ≥6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  3. Willing to discontinue the following: vaginal hormonal products; transdermal or oral estrogen or estrogen/progestin combination; intrauterine progestin; progestin implants; injectable estrogen; topical progesterone cream.
  4. Had to have daily average of ≥7 moderate to severe hot flashes and had to complete ≥4 days of diary entries during baseline week to be randomized.
  5. If treated with antidepressants, could not have had any changes in drug doses during past month.

Other Inclusions apply.

Exclusion Criteria:

  1. Patient treated with a gonadotrophin releasing hormone agonist, anti-estrogens, or aromatase inhibitors within 2 months prior to study entry.
  2. Patient treated with estrogen pellets or progestin injectable drugs within 6 months prior to study entry.
  3. Patient experience only nighttime hot flashes or worked night shifts on a regular basis.
  4. Patient was concurrently treated with gabapentin for other indications. If patient was using gabapentin for treatment of hot flashes, she could be screened after a 7-day washout period provided hot flashes returned.
  5. Patient had previously experienced dose-limiting adverse effects that prevented titration of gabapentin to an effective dose.
  6. Patient had a hypersensitivity to gabapentin.
  7. Patient was in an immunocompromised state.
  8. Patient had a malignancy other than basal cell carcinoma within 2 years prior to study entry.
  9. Patient had gastric reduction surgery, severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome, uncontrolled inflammatory bowel disease, or unexplained weight loss.
  10. Patient had clinically significant abnormal chemistry or hematology results, or calculated glomerular filtration rate <60 mL/min.
  11. Patient had history of substance abuse within year prior to study entry.
  12. Patient was concurrently taking morphine.
  13. Patient had history of chronic hepatitis B or C, hepatitis within 3 months prior to study entry, or history of human immunodeficiency virus.

Other Exclusions apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00777023

  Show 45 Study Locations
Sponsors and Collaborators
Depomed
  More Information

No publications provided

Responsible Party: Depomed
ClinicalTrials.gov Identifier: NCT00777023     History of Changes
Other Study ID Numbers: BREEZE 2, 81-0059
Study First Received: October 21, 2008
Results First Received: January 16, 2012
Last Updated: February 21, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Depomed:
Hot Flashes
Hot Flushes
Postmenopausal symptoms
Vasomotor symptoms

Additional relevant MeSH terms:
Hot Flashes
Signs and Symptoms
Gabapentin
Gamma-Aminobutyric Acid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents
GABA Agents

ClinicalTrials.gov processed this record on September 18, 2014